Ascus Biosciences uses a proprietary technology platform to analyze native microbial communities in highly productive animals and select efficacious native microorganisms for product development. The company develops novel, multi-strain, naturally occurring whole-microbe products that are shelf-stabilized and compatible with standard in‑feed delivery systems. Ascus positions its approach as the first in the animal health and nutrition industry based on a comprehensive understanding of animal microbiomes. It has multiple microbial solutions in development, with some already in sales across dairy, poultry, beef feedlot, equine, and companion species. Headquartered in San Diego, Ascus maintains field, sales, and production operations globally. With the newly secured funding, the company plans to expand customer sales and service teams, advance products in its pipeline, and continue refining its core technology platform and intellectual property.

Total raised

$46M

Funding rounds

1

Latest round

Series B

Latest activity

May 2020